{"id":14606,"date":"2023-05-25T21:36:07","date_gmt":"2023-05-26T01:36:07","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/?post_type=private_project&p=14606"},"modified":"2025-02-28T13:55:26","modified_gmt":"2025-02-28T18:55:26","slug":"real-world-outcomes-and-costs-of-osteoporosis-fractures-in-ontario-canada","status":"publish","type":"private_project","link":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/real-world-outcomes-and-costs-of-osteoporosis-fractures-in-ontario-canada\/","title":{"rendered":"Real World Outcomes and Costs of Osteoporosis Fractures in Ontario, Canada"},"content":{"rendered":"\n

Client:<\/strong> Amgen Canada Inc.

Project ID:<\/strong> P2017-018 \/ 2018 0970 103 000<\/p>\n\n\n\n

Research Question\/Objectives:<\/strong> Osteoporosis and the clinical fractures associated with the disease have significant consequences on human health and quality of life and represent a major burden to society. As with many other chronic and asymptomatic diseases, osteoporosis is under diagnosed and undertreated. The rates of treatment for osteoporosis are also sub-optimal, even among patients who have suffered hip or other fragility fractures. Studies conducted in a variety of different populations indicate that the rates of BMD testing and treatment following fragility fractures are generally <50%, and often <10%. The purpose of this study will be to describe the real-world management (including screening and treatment) and Health Resource Utilization (HRU) of patients subsequent to a primary fragility fracture in Ontario, Canada.<\/p>\n\n\n\n

Research Objectives<\/h2>\n\n\n\n

Primary Objectives:<\/strong><\/p>\n\n\n\n